Psoriasis and metabolic syndrome.
Psoriasis is a chronic inflammatory and immune-mediated disease associated with several comorbidities, such as obesity, hypertension, diabetes mellitus, dyslipidemia and cardiovascular disorder. These comorbidities are components of metabolic syndrome. The pathogenesis of metabolic syndrome is supposed to be related to increased levels of adipocytokines, such as tumor necrosis factor-α (TNF-α) and adiponectin. Recent study has revealed a high prevalence of metabolic syndrome in psoriatics compared with other skin diseases. Biologic agents, including anti-TNF-α antibodies, are recommended as the first-line treatment for psoriatics with metabolic syndrome. This article reviews the association of psoriasis and metabolic syndrome in terms of adipocytokines and evaluates the role of biologic agents in the treatment of psoriasis.
Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan. ht@asahikawa-med.ac.jp
Hidetoshi
H
Takahashi
Hajime
H
Iizuka
D052242:Adiponectin / Q000097:blood; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007155:Immunologic Factors / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000453:epidemiology*; D009765:Obesity / Q000453:epidemiology; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000097:blood
D052242:Adiponectin; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha